Italia markets close in 1 hour 53 minutes

RPRX May 2024 27.500 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,4400+0,3900 (+780,00%)
In data: 03:23PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,0500
Aperto0,3000
Denaro0,1000
Lettera0,9000
Prezzo d'esercizio27,50
Scadenza2024-05-17
Min-Max giorno0,2000 - 0,7500
Contratto - Min-MaxN/D
Volume11
Open Interest71
  • GlobeNewswire

    Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023

    NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events to obtain conference

  • GlobeNewswire

    Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

    NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology Officer, and a member of the Executive Leadership Team. During his tenur

  • GlobeNewswire

    Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

    • Proceeds to support continued development and commercialization of Endocrine Rare Disease products and general corporate purposes NEW YORK and COPENHAGEN, Denmark, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma has entered into a $150 million capped synthetic royalty funding agreement with Ascendis based on U.S. net Skytrofa revenue. “This transaction reflects the significant value of Skytrofa. We